Corcept Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Corcept Therapeutics Incorporated

31/07/2025 22:01

Corcept Therapeutics Inc CORT.OQ reported quarterly adjusted earnings of 29 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 32 cents.  The mean expectation of four analysts for the quarter was for earnings of 19 cents per share. Wall Street expected results to range from 7 cents to 30 cents per share.

Revenue rose 18.7% to $194.43 million from a year ago; analysts expected $199.39 million.

Corcept Therapeutics Inc's reported EPS for the quarter was 29 cents​.

The company reported quarterly net income of $34.61 million.

Corcept Therapeutics Inc shares had fallen by 4.8% this quarter and gained 38.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 50.3% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Corcept Therapeutics Inc is $138.50, about 49.5% above its last closing price of $69.91

This summary was machine generated from LSEG data July 31 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
0.19
0.29
Beat
Mar. 31 2025
0.14
0.17
Beat
Dec. 31 2024
0.43
0.26
Missed
Sep. 30 2024
0.28
0.41
Beat